These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27593107)

  • 1. Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy.
    Bittner MI; Wiedenmann N; Bucher S; Hentschel M; Mix M; Rücker G; Weber WA; Meyer PT; Werner M; Grosu AL; Kayser G
    Acta Oncol; 2016 Nov; 55(11):1299-1304. PubMed ID: 27593107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome.
    Wiedenmann NE; Bucher S; Hentschel M; Mix M; Vach W; Bittner MI; Nestle U; Pfeiffer J; Weber WA; Grosu AL
    Radiother Oncol; 2015 Oct; 117(1):113-7. PubMed ID: 26432067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy.
    Bittner MI; Wiedenmann N; Bucher S; Hentschel M; Mix M; Weber WA; Grosu AL
    Radiother Oncol; 2013 Sep; 108(3):511-6. PubMed ID: 23849686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy.
    Zschaeck S; Löck S; Leger S; Haase R; Bandurska-Luque A; Appold S; Kotzerke J; Zips D; Richter C; Gudziol V; Schreiber A; Zöphel K; Baumann M; Krause M
    Radiother Oncol; 2017 Mar; 122(3):437-444. PubMed ID: 28222892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal timing of fluorine-18-fluoromisonidazole positron emission tomography/computed tomography for assessment of tumor hypoxia in patients with head and neck squamous cell carcinoma.
    Chatterjee A; Gupta T; Rangarajan V; Purandare N; Kunder S; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal J
    Nucl Med Commun; 2018 Sep; 39(9):859-864. PubMed ID: 29939883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
    Moan JM; Amdal CD; Malinen E; Svestad JG; Bogsrud TV; Dale E
    Radiother Oncol; 2019 Nov; 140():54-61. PubMed ID: 31177043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
    Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic value of 18F-FDG PET, CT, and MRI in perineural spread of head and neck malignancies.
    Dercle L; Hartl D; Rozenblum-Beddok L; Mokrane FZ; Seban RD; Yeh R; Bidault F; Ammari S
    Eur Radiol; 2018 Apr; 28(4):1761-1770. PubMed ID: 29086023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.
    Nicolay NH; Wiedenmann N; Mix M; Weber WA; Werner M; Grosu AL; Kayser G
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1046-1055. PubMed ID: 31811344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.
    Kroenke M; Hirata K; Gafita A; Watanabe S; Okamoto S; Magota K; Shiga T; Kuge Y; Tamaki N
    PLoS One; 2019; 14(2):e0213111. PubMed ID: 30818360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET.
    Grönroos TJ; Lehtiö K; Söderström KO; Kronqvist P; Laine J; Eskola O; Viljanen T; Grénman R; Solin O; Minn H
    BMC Cancer; 2014 Nov; 14():876. PubMed ID: 25421331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma.
    Bogowicz M; Riesterer O; Stark LS; Studer G; Unkelbach J; Guckenberger M; Tanadini-Lang S
    Acta Oncol; 2017 Nov; 56(11):1531-1536. PubMed ID: 28820287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
    Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
    Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
    Mainta IC; Zilli T; Tille JC; De Perrot T; Vallée JP; Buchegger F; Garibotto V; Miralbell R
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1210-1218. PubMed ID: 29678527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the accuracy of target volume delineation by combined use of computed tomography, magnetic resonance imaging and positron emission tomography in head and neck carcinomas.
    Chauhan D; Rawat S; Sharma MK; Ahlawat P; Pal M; Gupta G; Dewan A; Gupta M; Sharma S; Dodagoudar C; Pahuja A; Mitra S; Sharma SK
    J Cancer Res Ther; 2015; 11(4):746-51. PubMed ID: 26881512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
    Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
    Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma.
    Koyasu S; Nakamoto Y; Kikuchi M; Suzuki K; Hayashida K; Itoh K; Togashi K
    AJR Am J Roentgenol; 2014 Apr; 202(4):851-8. PubMed ID: 24660716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
    McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
    Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.
    Zips D; Zöphel K; Abolmaali N; Perrin R; Abramyuk A; Haase R; Appold S; Steinbach J; Kotzerke J; Baumann M
    Radiother Oncol; 2012 Oct; 105(1):21-8. PubMed ID: 23022173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.